FDA Not Writing A “Breakthrough” Guidance – Yet
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The agency needs more experience making the decisions before it lays out the evidence threshold for a breakthrough designation, CDER Director Janet Woodcock says.
You may also be interested in...
Industry Wants A Breakthrough Therapy, Even Without All The Standards
A few requests have gone to FDA for candidates to be named breakthrough therapies and gain access to shorter development programs, but the agency has not established all the program requirements yet.
FDA To Provide Expedited Approval Desktop Reference
Comprehensive guidance document is expected to describe FDASIA changes and clarify terms that have become confusing as more pathways emerge to speed drug approvals.
FDA, EMA Seek Biosimilar Pathway Convergence
The deputy director of FDA's Europe Office discusses the collaboration between FDA and the European Medicines Agency; the agencies are looking for ways to develop a common biosimilar development program.